JavascriptがOFFのため正しく表示されない可能性があります。
日本語
Sitemap
About AskAt
Portfolio
Business Model
Corporate Information
IR Information
Contact
Home
NEWS
NEWS
2023
business
2023/01/11
Combined Clinical Trial Application of Cannabinoid CB2 Receptor Agonist AAT-730 for First-In-Human Clinical Trial has been submitted by Oxford Cannabinoid Technologies to UK Regulatory Agencies
Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO:Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced that a combined clinical trial application for AAT-730 (OCT461201) has been successfully submitted to UK Medicines & Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) on January 4th, 2023.
science
2023/01/11
Ikena Oncology presented results of a clinical trial of grapiprant (AAT-007/IK-007) in patients with advanced microsatellite stable colorectal cancer
Ikena Oncology presented results of a clinical trial of IK-007 in patients with advanced microsatellite stable colorectal cancer at ESMO Immuno-Oncology Annual Congress 2022. For details, please refer an abstract of the presentation at congress homepage.
patent
2023/01/06
European Patent Office Grants AskAt EP4 Receptor Antagonist Use Patent for the Treatment of Cartilage Disease
AskAt received a notice of the decision to grant a European patent pursuant to Article 97(1) EPC from the European Patent Office as of December 8, 2022. This grant of European Patent Application No. 14768803.0 (Filing Date: March 19, 2014), is an EP4 receptor antagonist use patent for the treatment of cartilage disease.
NEWS
2023
2022
2021
2020
2019
2018
2017
2016
2015
2013
Menu
Close
About AskAt
Portfolio
Business Model
Corporate Information
Message from the Chairman
Philosophy and Vision
Profile and History
Company Name and Logo Mark
IR information
Contact
News
Sitemap
日本語
Close